Equities analysts expect Nabriva Therapeutics PLC – (NASDAQ:NBRV) to announce earnings per share (EPS) of ($0.33) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Nabriva Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.30). Nabriva Therapeutics reported earnings of ($0.44) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The firm is scheduled to issue its next earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Nabriva Therapeutics will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.31) to ($0.71). For the next year, analysts expect that the business will post earnings of ($0.89) per share, with EPS estimates ranging from ($1.22) to ($0.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. Nabriva Therapeutics had a negative net margin of 3,194.72% and a negative return on equity of 119.75%. The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $0.56 million.

A number of brokerages have recently commented on NBRV. BidaskClub cut shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Northland Securities reaffirmed a “buy” rating and set a $12.50 price objective on shares of Nabriva Therapeutics in a research note on Tuesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Nabriva Therapeutics in a research note on Thursday, May 9th. Finally, ValuEngine cut shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. Nabriva Therapeutics has an average rating of “Buy” and a consensus price target of $7.28.

A number of institutional investors have recently added to or reduced their stakes in the stock. Aisling Capital Management LP purchased a new position in shares of Nabriva Therapeutics during the 4th quarter worth $2,642,000. Jane Street Group LLC purchased a new position in shares of Nabriva Therapeutics during the 4th quarter worth $29,000. Renaissance Technologies LLC raised its holdings in shares of Nabriva Therapeutics by 2,128.9% during the 3rd quarter. Renaissance Technologies LLC now owns 285,300 shares of the biotechnology company’s stock worth $770,000 after acquiring an additional 272,500 shares during the period. Fosun International Ltd purchased a new position in shares of Nabriva Therapeutics during the 1st quarter worth $1,593,000. Finally, FMR LLC raised its holdings in shares of Nabriva Therapeutics by 514.2% during the 4th quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock worth $2,690,000 after acquiring an additional 1,542,700 shares during the period. 4.18% of the stock is currently owned by hedge funds and other institutional investors.

NBRV traded down $0.09 during trading on Wednesday, reaching $2.01. 459,986 shares of the company’s stock were exchanged, compared to its average volume of 1,047,483. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $4.60. The company has a current ratio of 5.55, a quick ratio of 5.55 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $1.39 billion, a PE ratio of -1.23 and a beta of 2.47.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: Asset Allocation

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.